Show simple item record

dc.contributor.authorPaniagua Gómez-Álvarez, Ricardo 
dc.contributor.authorFraile Laiz, Benito 
dc.contributor.authorArenas Jiménez, María Isabel 
dc.contributor.authorLucio Cazaña, Francisco Javier de 
dc.contributor.authorConde Martín, María Isabel 
dc.date.accessioned2018-03-14T12:52:16Z
dc.date.available2018-03-14T12:52:16Z
dc.date.issued2008-07-13
dc.identifier.bibliographicCitationHistology and Histopathology. 2008, v. 23, n. 1, p. 77-85en
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10017/32724
dc.description.abstractGlucocorticoids play a major role in attenuation of the inflammatory response and they are useful in the primary combination chemotherapy of breast cancer, since in vitro studies have demonstrated an antiproliferative effect in human breast cancer cells. In contrast, it was recently shown that glucocorticoids protect against apoptotic signals evoked by cytokines, cAMP, tumour suppressors, and death genes in mammary gland epithelia. Their actions are mediated by intracellular receptor (GR) that functions as a hormone-dependent transcription factor; however, no previous studies have been focused on GR expression in different pathologies of the human breast, and the possible relationship with that of mineralocorticoid receptor (MR) and COX-2. Also, the role of these proteins on tumoral breast epithelial cells remains unclear. Therefore, we examined GR, MR and COX-2 expression by immunohistochemistry and Western blot techniques in 142 samples of human breast obtained by total or partial mastectomy. We found that the percentage of positive patients presenting nuclear immunoreaction to GR decreased with tumor development, while all samples analyzed showed cytoplasmic immunoreactions to MR. All positive samples to COX-2 antibody showed cytoplasmic location, a higher immunoreaction being observed in benign breast diseases than in carcinomatous lesions. Thus, breast cancer progression is associated with the accumulation of GR in the cytoplasm of tumoral cells and the decrease of COX-2 expression.en
dc.format.mimetypeapplication/pdfen
dc.language.isoengen
dc.publisherSercrisma International S.L.en
dc.rights© Sercrisma International S.L., 2008en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectGRen
dc.subjectMRen
dc.subjectCOX-2en
dc.subjectBreast canceren
dc.titleGlucocorticoid receptor changes its cellular location with breast cancer development.en
dc.typeinfo:eu-repo/semantics/articleen
dc.subject.ecienciaBiologíaen
dc.subject.ecienciaBiologyen
dc.subject.ecienciaGenéticaes_ES
dc.subject.ecienciaGeneticsen
dc.subject.ecienciaCIENCIAes_ES
dc.subject.ecienciaSCIENCEen
dc.contributor.affiliationUniversidad de Alcalá. Departamento de Biomedicina y Biotecnología. Unidad docente Biología Celular y Genéticaes_ES
dc.relation.publisherversionhttps://doi.org/10.14670/HH-23.77
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.identifier.doi10.14670/HH-23.77
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen
dc.identifier.publicationtitleHistology and histopathologyen
dc.identifier.publicationvolume23
dc.identifier.publicationlastpage85
dc.identifier.publicationissue1
dc.identifier.publicationfirstpage77
dc.identifier.pmid17952860
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshBreasten
dc.subject.meshBreast Neoplasmsen
dc.subject.meshCarcinoma in Situen
dc.subject.meshCarcinoma, Ductalen
dc.subject.meshCarcinoma, Lobularen
dc.subject.meshCyclooxygenase 2en
dc.subject.meshFemaleen
dc.subject.meshFibroadenomaen
dc.subject.meshHumansen
dc.subject.meshHyperplasiaen
dc.subject.meshMetaplasiaen
dc.subject.meshMiddle Ageden
dc.subject.meshReceptors, Glucocorticoiden
dc.subject.meshReceptors, Mineralocorticoiden
dc.identifier.essn1699-5848


Files in this item

Thumbnail

This item appears in the following Collection(s)

© Sercrisma International S.L., 2008
Este ítem está sujeto a una licencia Creative Commons.